A Phase 1, Open-label, Dose Finding Study of CC-90009 in Subjects With Relapsed, Refractory Acute Myeloid Leukemia

What is the purpose of this trial?

CC-90009-AML-001 is a phase 1, open-label, dose escalation and expansion, study in subjects with relapsed or refractory acute myeloid leukemia

Celgene Corporation

Start Date: 08/14/2017

End Date: 08/01/2019

Last Updated: 02/22/2018

Study HIC#: 2000020835

Get Involved

For more information about this study, contact:
Tanya Malak
+1 203-785-4699

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image